Phase IIa/IIb Clinical Trial of NC-6004 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Have Failed Platinum or a Platinum-containing Regimen
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Cisplatin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NanoCarrier
- 21 Jul 2019 Status changed from not yet recruiting to recruiting.
- 25 Apr 2019 Planned initiation date changed from 1 Feb 2019 to 1 Jun 2019.
- 09 Dec 2018 Status changed from planning to not yet recruiting.